Infusion of Reconstituted High-Density Lipoprotein Leads to Acute Changes in Human Atherosclerotic Plaque

Studies have shown a reduction in plaque volume and change in plaque ultrasound characteristics after 4 infusions of reconstituted high-density lipoprotein (rHDL). Whether rHDL infusion leads to acute changes in plaque characteristics in humans is not known. Patients with claudication scheduled for...

Full description

Saved in:
Bibliographic Details
Published in:Circulation research 2008-11, Vol.103 (10), p.1084-1091
Main Authors: Shaw, James A, Bobik, Alex, Murphy, Andrew, Kanellakis, Peter, Blombery, Peter, Mukhamedova, Nigora, Woollard, Kevin, Lyon, Stuart, Sviridov, Dmitri, Dart, Anthony M
Format: Article
Language:English
Subjects:
Aged
Aspirin - administration & dosage
Atherosclerosis (general aspects, experimental research)
Biological and medical sciences
Blood and lymphatic vessels
Cardiology. Vascular system
Cardiotonic Agents - administration & dosage
Cholesterol, HDL - blood
Coronary Artery Disease - blood
Coronary Artery Disease - diet therapy
Female
Fibrinolytic Agents - administration & dosage
Gene Expression Regulation - drug effects
Humans
Infusions, Intravenous
Lipoproteins, HDL - administration & dosage
Male
Medical sciences
Middle Aged
Vascular Cell Adhesion Molecule-1 - blood
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c5867-9ec1eb42556fc274bd5b719bdadee7b2a11afbf1159a8a17cf39971016f79a863
cites cdi_FETCH-LOGICAL-c5867-9ec1eb42556fc274bd5b719bdadee7b2a11afbf1159a8a17cf39971016f79a863
container_end_page 1091
container_issue 10
container_start_page 1084
container_title Circulation research
container_volume 103
creator Shaw, James A
Bobik, Alex
Murphy, Andrew
Kanellakis, Peter
Blombery, Peter
Mukhamedova, Nigora
Woollard, Kevin
Lyon, Stuart
Sviridov, Dmitri
Dart, Anthony M
description Studies have shown a reduction in plaque volume and change in plaque ultrasound characteristics after 4 infusions of reconstituted high-density lipoprotein (rHDL). Whether rHDL infusion leads to acute changes in plaque characteristics in humans is not known. Patients with claudication scheduled for percutaneous superficial femoral artery revascularization were randomized to receive 1 intravenous infusion of either placebo or rHDL (80 mg/kg given over 4 hours). Five to 7 days following the infusion, patients returned and revascularization was performed including atherectomy to excise plaque from the superficial femoral artery. Twenty patients (17 males) average age, 68±10 years (mean±SD) were recruited. Eleven patients had a history of documented coronary artery disease, all patients were on aspirin, and 18 were on statins. Ten of the patients received rHDL and 10 placebo. There was significantly less vascular cell adhesion molecule-1 expression (28±3% versus 50±3%; P
doi_str_mv 10.1161/CIRCRESAHA.108.182063
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_69764311</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>69764311</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5867-9ec1eb42556fc274bd5b719bdadee7b2a11afbf1159a8a17cf39971016f79a863</originalsourceid><addsrcrecordid>eNpFkU1v1DAQhi0EapfSnwDyhd6yeOwkdo5R2rIrrQRa4Gw5zrgxZJMldlT13-PVruhlRnrnmQ-9Q8hHYGuAEr40232zf_hRb-o1MLUGxVkp3pAVFDzP8kLCW7JijFWZFIJdk_ch_GYMcsGrK3INSgkuC1gRvx3dEvw00snRPdppDNHHJWJHN_6pz-5xDD6-0J0_Tsd5iuhHukPTBRonWtsE0qY34xMGmiqb5WBGWsce5ynYIcXoLf0-mL8LfiDvnBkC3l7yDfn1-PCz2WS7b1-3Tb3LbKFKmVVoAducF0XpLJd52xWthKrtTIcoW24AjGsdQFEZZUBaJ6pKAoPSyaSU4obcneemc9PaEPXBB4vDYEaclqDLSpa5AEhgcQZtOjbM6PRx9gczv2hg-uSxfvU4SUqfPU59ny4LlvaA3WvXxdQEfL4AJlgzuNmM1of_HGdKyEqduPzMPU9DxDn8GZZnnHWPZoi9Ts9jggHPOGMKgEmWnSQp_gGhnJYq</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>69764311</pqid></control><display><type>article</type><title>Infusion of Reconstituted High-Density Lipoprotein Leads to Acute Changes in Human Atherosclerotic Plaque</title><source>Freely Accessible Science Journals</source><creator>Shaw, James A ; Bobik, Alex ; Murphy, Andrew ; Kanellakis, Peter ; Blombery, Peter ; Mukhamedova, Nigora ; Woollard, Kevin ; Lyon, Stuart ; Sviridov, Dmitri ; Dart, Anthony M</creator><creatorcontrib>Shaw, James A ; Bobik, Alex ; Murphy, Andrew ; Kanellakis, Peter ; Blombery, Peter ; Mukhamedova, Nigora ; Woollard, Kevin ; Lyon, Stuart ; Sviridov, Dmitri ; Dart, Anthony M</creatorcontrib><description>Studies have shown a reduction in plaque volume and change in plaque ultrasound characteristics after 4 infusions of reconstituted high-density lipoprotein (rHDL). Whether rHDL infusion leads to acute changes in plaque characteristics in humans is not known. Patients with claudication scheduled for percutaneous superficial femoral artery revascularization were randomized to receive 1 intravenous infusion of either placebo or rHDL (80 mg/kg given over 4 hours). Five to 7 days following the infusion, patients returned and revascularization was performed including atherectomy to excise plaque from the superficial femoral artery. Twenty patients (17 males) average age, 68±10 years (mean±SD) were recruited. Eleven patients had a history of documented coronary artery disease, all patients were on aspirin, and 18 were on statins. Ten of the patients received rHDL and 10 placebo. There was significantly less vascular cell adhesion molecule-1 expression (28±3% versus 50±3%; P&lt;0.05) and a reduction in lipid content in the plaque of HDL-treated subjects compared to placebo. The level of HDL cholesterol increased by 20% after infusion of rHDL and the capacity of apolipoprotein B–depleted plasma to support cholesterol efflux increased. Intravenous infusion of a single dose of reconstituted HDL led to acute changes in plaque characteristics with a reduction in lipid content, macrophage size, and measures of inflammation. These changes may contribute to the cardioprotective effects of HDL.</description><identifier>ISSN: 0009-7330</identifier><identifier>EISSN: 1524-4571</identifier><identifier>DOI: 10.1161/CIRCRESAHA.108.182063</identifier><identifier>PMID: 18832751</identifier><identifier>CODEN: CIRUAL</identifier><language>eng</language><publisher>Hagerstown, MD: American Heart Association, Inc</publisher><subject>Aged ; Aspirin - administration &amp; dosage ; Atherosclerosis (general aspects, experimental research) ; Biological and medical sciences ; Blood and lymphatic vessels ; Cardiology. Vascular system ; Cardiotonic Agents - administration &amp; dosage ; Cholesterol, HDL - blood ; Coronary Artery Disease - blood ; Coronary Artery Disease - diet therapy ; Female ; Fibrinolytic Agents - administration &amp; dosage ; Gene Expression Regulation - drug effects ; Humans ; Infusions, Intravenous ; Lipoproteins, HDL - administration &amp; dosage ; Male ; Medical sciences ; Middle Aged ; Vascular Cell Adhesion Molecule-1 - blood</subject><ispartof>Circulation research, 2008-11, Vol.103 (10), p.1084-1091</ispartof><rights>2008 American Heart Association, Inc.</rights><rights>2008 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5867-9ec1eb42556fc274bd5b719bdadee7b2a11afbf1159a8a17cf39971016f79a863</citedby><cites>FETCH-LOGICAL-c5867-9ec1eb42556fc274bd5b719bdadee7b2a11afbf1159a8a17cf39971016f79a863</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=20837981$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/18832751$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Shaw, James A</creatorcontrib><creatorcontrib>Bobik, Alex</creatorcontrib><creatorcontrib>Murphy, Andrew</creatorcontrib><creatorcontrib>Kanellakis, Peter</creatorcontrib><creatorcontrib>Blombery, Peter</creatorcontrib><creatorcontrib>Mukhamedova, Nigora</creatorcontrib><creatorcontrib>Woollard, Kevin</creatorcontrib><creatorcontrib>Lyon, Stuart</creatorcontrib><creatorcontrib>Sviridov, Dmitri</creatorcontrib><creatorcontrib>Dart, Anthony M</creatorcontrib><title>Infusion of Reconstituted High-Density Lipoprotein Leads to Acute Changes in Human Atherosclerotic Plaque</title><title>Circulation research</title><addtitle>Circ Res</addtitle><description>Studies have shown a reduction in plaque volume and change in plaque ultrasound characteristics after 4 infusions of reconstituted high-density lipoprotein (rHDL). Whether rHDL infusion leads to acute changes in plaque characteristics in humans is not known. Patients with claudication scheduled for percutaneous superficial femoral artery revascularization were randomized to receive 1 intravenous infusion of either placebo or rHDL (80 mg/kg given over 4 hours). Five to 7 days following the infusion, patients returned and revascularization was performed including atherectomy to excise plaque from the superficial femoral artery. Twenty patients (17 males) average age, 68±10 years (mean±SD) were recruited. Eleven patients had a history of documented coronary artery disease, all patients were on aspirin, and 18 were on statins. Ten of the patients received rHDL and 10 placebo. There was significantly less vascular cell adhesion molecule-1 expression (28±3% versus 50±3%; P&lt;0.05) and a reduction in lipid content in the plaque of HDL-treated subjects compared to placebo. The level of HDL cholesterol increased by 20% after infusion of rHDL and the capacity of apolipoprotein B–depleted plasma to support cholesterol efflux increased. Intravenous infusion of a single dose of reconstituted HDL led to acute changes in plaque characteristics with a reduction in lipid content, macrophage size, and measures of inflammation. These changes may contribute to the cardioprotective effects of HDL.</description><subject>Aged</subject><subject>Aspirin - administration &amp; dosage</subject><subject>Atherosclerosis (general aspects, experimental research)</subject><subject>Biological and medical sciences</subject><subject>Blood and lymphatic vessels</subject><subject>Cardiology. Vascular system</subject><subject>Cardiotonic Agents - administration &amp; dosage</subject><subject>Cholesterol, HDL - blood</subject><subject>Coronary Artery Disease - blood</subject><subject>Coronary Artery Disease - diet therapy</subject><subject>Female</subject><subject>Fibrinolytic Agents - administration &amp; dosage</subject><subject>Gene Expression Regulation - drug effects</subject><subject>Humans</subject><subject>Infusions, Intravenous</subject><subject>Lipoproteins, HDL - administration &amp; dosage</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Vascular Cell Adhesion Molecule-1 - blood</subject><issn>0009-7330</issn><issn>1524-4571</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2008</creationdate><recordtype>article</recordtype><recordid>eNpFkU1v1DAQhi0EapfSnwDyhd6yeOwkdo5R2rIrrQRa4Gw5zrgxZJMldlT13-PVruhlRnrnmQ-9Q8hHYGuAEr40232zf_hRb-o1MLUGxVkp3pAVFDzP8kLCW7JijFWZFIJdk_ch_GYMcsGrK3INSgkuC1gRvx3dEvw00snRPdppDNHHJWJHN_6pz-5xDD6-0J0_Tsd5iuhHukPTBRonWtsE0qY34xMGmiqb5WBGWsce5ynYIcXoLf0-mL8LfiDvnBkC3l7yDfn1-PCz2WS7b1-3Tb3LbKFKmVVoAducF0XpLJd52xWthKrtTIcoW24AjGsdQFEZZUBaJ6pKAoPSyaSU4obcneemc9PaEPXBB4vDYEaclqDLSpa5AEhgcQZtOjbM6PRx9gczv2hg-uSxfvU4SUqfPU59ny4LlvaA3WvXxdQEfL4AJlgzuNmM1of_HGdKyEqduPzMPU9DxDn8GZZnnHWPZoi9Ts9jggHPOGMKgEmWnSQp_gGhnJYq</recordid><startdate>20081107</startdate><enddate>20081107</enddate><creator>Shaw, James A</creator><creator>Bobik, Alex</creator><creator>Murphy, Andrew</creator><creator>Kanellakis, Peter</creator><creator>Blombery, Peter</creator><creator>Mukhamedova, Nigora</creator><creator>Woollard, Kevin</creator><creator>Lyon, Stuart</creator><creator>Sviridov, Dmitri</creator><creator>Dart, Anthony M</creator><general>American Heart Association, Inc</general><general>Lippincott</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20081107</creationdate><title>Infusion of Reconstituted High-Density Lipoprotein Leads to Acute Changes in Human Atherosclerotic Plaque</title><author>Shaw, James A ; Bobik, Alex ; Murphy, Andrew ; Kanellakis, Peter ; Blombery, Peter ; Mukhamedova, Nigora ; Woollard, Kevin ; Lyon, Stuart ; Sviridov, Dmitri ; Dart, Anthony M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5867-9ec1eb42556fc274bd5b719bdadee7b2a11afbf1159a8a17cf39971016f79a863</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2008</creationdate><topic>Aged</topic><topic>Aspirin - administration &amp; dosage</topic><topic>Atherosclerosis (general aspects, experimental research)</topic><topic>Biological and medical sciences</topic><topic>Blood and lymphatic vessels</topic><topic>Cardiology. Vascular system</topic><topic>Cardiotonic Agents - administration &amp; dosage</topic><topic>Cholesterol, HDL - blood</topic><topic>Coronary Artery Disease - blood</topic><topic>Coronary Artery Disease - diet therapy</topic><topic>Female</topic><topic>Fibrinolytic Agents - administration &amp; dosage</topic><topic>Gene Expression Regulation - drug effects</topic><topic>Humans</topic><topic>Infusions, Intravenous</topic><topic>Lipoproteins, HDL - administration &amp; dosage</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Vascular Cell Adhesion Molecule-1 - blood</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Shaw, James A</creatorcontrib><creatorcontrib>Bobik, Alex</creatorcontrib><creatorcontrib>Murphy, Andrew</creatorcontrib><creatorcontrib>Kanellakis, Peter</creatorcontrib><creatorcontrib>Blombery, Peter</creatorcontrib><creatorcontrib>Mukhamedova, Nigora</creatorcontrib><creatorcontrib>Woollard, Kevin</creatorcontrib><creatorcontrib>Lyon, Stuart</creatorcontrib><creatorcontrib>Sviridov, Dmitri</creatorcontrib><creatorcontrib>Dart, Anthony M</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Circulation research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Shaw, James A</au><au>Bobik, Alex</au><au>Murphy, Andrew</au><au>Kanellakis, Peter</au><au>Blombery, Peter</au><au>Mukhamedova, Nigora</au><au>Woollard, Kevin</au><au>Lyon, Stuart</au><au>Sviridov, Dmitri</au><au>Dart, Anthony M</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Infusion of Reconstituted High-Density Lipoprotein Leads to Acute Changes in Human Atherosclerotic Plaque</atitle><jtitle>Circulation research</jtitle><addtitle>Circ Res</addtitle><date>2008-11-07</date><risdate>2008</risdate><volume>103</volume><issue>10</issue><spage>1084</spage><epage>1091</epage><pages>1084-1091</pages><issn>0009-7330</issn><eissn>1524-4571</eissn><coden>CIRUAL</coden><abstract>Studies have shown a reduction in plaque volume and change in plaque ultrasound characteristics after 4 infusions of reconstituted high-density lipoprotein (rHDL). Whether rHDL infusion leads to acute changes in plaque characteristics in humans is not known. Patients with claudication scheduled for percutaneous superficial femoral artery revascularization were randomized to receive 1 intravenous infusion of either placebo or rHDL (80 mg/kg given over 4 hours). Five to 7 days following the infusion, patients returned and revascularization was performed including atherectomy to excise plaque from the superficial femoral artery. Twenty patients (17 males) average age, 68±10 years (mean±SD) were recruited. Eleven patients had a history of documented coronary artery disease, all patients were on aspirin, and 18 were on statins. Ten of the patients received rHDL and 10 placebo. There was significantly less vascular cell adhesion molecule-1 expression (28±3% versus 50±3%; P&lt;0.05) and a reduction in lipid content in the plaque of HDL-treated subjects compared to placebo. The level of HDL cholesterol increased by 20% after infusion of rHDL and the capacity of apolipoprotein B–depleted plasma to support cholesterol efflux increased. Intravenous infusion of a single dose of reconstituted HDL led to acute changes in plaque characteristics with a reduction in lipid content, macrophage size, and measures of inflammation. These changes may contribute to the cardioprotective effects of HDL.</abstract><cop>Hagerstown, MD</cop><pub>American Heart Association, Inc</pub><pmid>18832751</pmid><doi>10.1161/CIRCRESAHA.108.182063</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0009-7330
ispartof Circulation research, 2008-11, Vol.103 (10), p.1084-1091
issn 0009-7330
1524-4571
language eng
recordid cdi_proquest_miscellaneous_69764311
source Freely Accessible Science Journals
subjects Aged
Aspirin - administration & dosage
Atherosclerosis (general aspects, experimental research)
Biological and medical sciences
Blood and lymphatic vessels
Cardiology. Vascular system
Cardiotonic Agents - administration & dosage
Cholesterol, HDL - blood
Coronary Artery Disease - blood
Coronary Artery Disease - diet therapy
Female
Fibrinolytic Agents - administration & dosage
Gene Expression Regulation - drug effects
Humans
Infusions, Intravenous
Lipoproteins, HDL - administration & dosage
Male
Medical sciences
Middle Aged
Vascular Cell Adhesion Molecule-1 - blood
title Infusion of Reconstituted High-Density Lipoprotein Leads to Acute Changes in Human Atherosclerotic Plaque
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T14%3A42%3A51IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Infusion%20of%20Reconstituted%20High-Density%20Lipoprotein%20Leads%20to%20Acute%20Changes%20in%20Human%20Atherosclerotic%20Plaque&rft.jtitle=Circulation%20research&rft.au=Shaw,%20James%20A&rft.date=2008-11-07&rft.volume=103&rft.issue=10&rft.spage=1084&rft.epage=1091&rft.pages=1084-1091&rft.issn=0009-7330&rft.eissn=1524-4571&rft.coden=CIRUAL&rft_id=info:doi/10.1161/CIRCRESAHA.108.182063&rft_dat=%3Cproquest_cross%3E69764311%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c5867-9ec1eb42556fc274bd5b719bdadee7b2a11afbf1159a8a17cf39971016f79a863%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=69764311&rft_id=info:pmid/18832751&rfr_iscdi=true